Home > Compound List > Product Information
Vigabatrin_Molecular_structure_CAS_60643-86-9)
Click picture or here to close

Vigabatrin

Catalog No. DB01080 Name DrugBank
CAS Number 60643-86-9 Website http://www.ualberta.ca/
M. F. C6H11NO2 Telephone (780) 492-3111
M. W. 129.15704 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 951

SYNONYMS

IUPAC name
4-aminohex-5-enoic acid
IUPAC Traditional name
vigabatrin
Brand Name
GVG
4-Aminohexenoic acid
Vigabatrine [French]
Vigabatrina [Spanish]
4-Amino-5-hexenoic acid
Sabril (TN)
Vigabatrin [USAN:BAN:INN]
Vigabatrine
Vigabatrinum [Latin]
gamma-Vinyl GABA

DATABASE IDS

PubChem SID 46507052
PubChem CID 5665
CAS Number 60643-86-9

PROPERTIES

Hydrophobicity(logP) 0.1
Solubility 55.1 mg/mL

DETAILS

Description (English)
Item Information
Drug Groups approved
Description An analogue of gamma-aminobutyric acid. It is an irreversible inhibitor of 4-aminobutyrate transaminase, the enzyme responsible for the catabolism of gamma-aminobutyric acid. (From Martindale The Extra Pharmacopoeia, 31st ed)
Indication For use as an adjunctive treatment (with other drugs) in treatment resistant epilepsy, complex partial seizures, secondary generalized seizures, and for monotherapy use in infantile spasms in West syndrome.
Pharmacology Vigabatrin, is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin inhibits the catabolism of GABA. It is an analog of GABA, but it is not a receptor agonist. Vigabatrin irreversibly inhibits the enzyme GABA transaminase.
Affected Organisms
Humans and other mammals
Biotransformation Almost no metabolic transformation. Does not induce the hepatic cytochrome P450 system.
Absorption Rapidly absorbed following oral administration. Food may slightly decrease the rate, but not the extent, of absorption.
Half Life 5-8 hours in young adults, 12-13 hours in elderly.
Protein Binding Little to none
Elimination Vigabatrin is not significantly metabolized; it is eliminated primarily through renal excretion.
Distribution * 1.1 L/kg
Clearance * 2.4 +/- 0.8 L/h [Infant]
* 5.7 +/- 2.5 L/h [Children]
References
Gram L, Larsson OM, Johnsen A, Schousboe A: Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol. 1989;27 Suppl 1:13S-17S. [Pubmed]
Browne TR: Pharmacokinetics of antiepileptic drugs. Neurology. 1998 Nov;51(5 Suppl 4):S2-7. [Pubmed]
Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T: Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003 Aug;25(4):457-62. [Pubmed]
Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller HJ, Rupprecht R: Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001 Nov;25(5):699-703. [Pubmed]
External Links
Wikipedia
Drugs.com

REFERENCES

  • Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller HJ, Rupprecht R: Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001 Nov;25(5):699-703. Pubmed
  • Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T: Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003 Aug;25(4):457-62. Pubmed
  • Browne TR: Pharmacokinetics of antiepileptic drugs. Neurology. 1998 Nov;51(5 Suppl 4):S2-7. Pubmed
  • Gram L, Larsson OM, Johnsen A, Schousboe A: Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol. 1989;27 Suppl 1:13S-17S. Pubmed